114 related articles for article (PubMed ID: 20014880)
1. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
[No Abstract] [Full Text] [Related]
2. Neurosurgeons achieve world's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
Future Oncol; 2010 Jan; 6(1):9. PubMed ID: 20021203
[No Abstract] [Full Text] [Related]
3. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
5. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Wilkes GM
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
[No Abstract] [Full Text] [Related]
6. Monitoring therapeutic monoclonal antibodies in brain tumor.
Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
[TBL] [Abstract][Full Text] [Related]
7. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
[TBL] [Abstract][Full Text] [Related]
8. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
9. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Chamberlain MC; Raizer J; Schiff D; Sherman JH
Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
[No Abstract] [Full Text] [Related]
10. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
Lomax AJ; Hill PA; Ashley DM
J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
[TBL] [Abstract][Full Text] [Related]
11. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.
Keenan BP; Abuav R
Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324
[No Abstract] [Full Text] [Related]
12. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
Henriksson R; Bergström P; Johansson M; Sandström M
Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
[No Abstract] [Full Text] [Related]
13. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA
J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049
[TBL] [Abstract][Full Text] [Related]
14. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
15. Integrins as target: first phase III trial launches, but questions remain.
Carter A
J Natl Cancer Inst; 2010 May; 102(10):675-7. PubMed ID: 20460633
[No Abstract] [Full Text] [Related]
16. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Sherman JH; Aregawi DG; Lai A; Fathallah-Shaykh HM; Bierman PJ; Linsky K; Larner JM; Newman SA; Schiff D
Neurology; 2009 Dec; 73(22):1924-6. PubMed ID: 19949039
[No Abstract] [Full Text] [Related]
17. Fewer dollars, more sense.
Garfield DH; Hercbergs A
J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
[No Abstract] [Full Text] [Related]
18. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
19. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
